Table 2.

Compliance with advertising guidelines of the websites regarding prescription drug misuse of glucagon-like peptide-1 receptor agonists by off-label use for weight loss (N=87).

		Values, n (%)
Content that should be includeda
	The drug is unapproved	43 (49)
	Acquisition route	69 (79)
	Information on whether there are other domestically approved drugs with the same ingredients and performance	24 (28)
	Information on the safety of the drug in other countries	69 (79)
	Ineligible for relief system for sufferers from adverse drug reactions	8 (9)
Exaggerated advertisementsb		72 (83)

^aExplicit statements required under Japan’s medical advertising guidelines for noninsured medical treatments involving off-label drug use.

^bAdvertisements containing expressions that could mislead citizens, as determined by coders under Japan’s medical advertising guidelines.